2,044 events on record Subscribe September 10, 2026
Standing Record home The Standing Record A non-partisan record of US democratic norms —
and the events that erode them.

Kentucky enacted HB501, barring Medicaid from covering cross-sex hormones for gender-dysphoria treatment

On April 10, 2025, Kentucky House Bill 501 became law without Gov. Andy Beshear's signature after passing the House 97-0 and the Senate 38-0. The act codified that Kentucky Medicaid may not fund cross-sex hormones when they are prescribed primarily or solely to treat gender dysphoria, singling out transgender-related use for exclusion while allowing the same drugs for other conditions. It refined a companion measure, HB495, that had restricted Medicaid coverage of gender-affirming care.

Jurisdiction
Kentucky
Location
Frankfort, Kentucky

Abuses documented

Actors

Kentucky House Bill 501, styled "AN ACT relating to pharmaceutical drugs," became law on April 10, 2025, without the signature of Gov. Andy Beshear, after clearing the House 97-0 and the Senate 38-0. Alongside provisions governing pharmacist dispensing, the act amended Kentucky's Medicaid statutes to bar the program from spending funds on cross-sex hormones when those drugs are prescribed or administered primarily or solely to treat gender dysphoria.

The exclusion reaches only transgender-related use: the same hormones remain reimbursable when prescribed for other medical indications. HB501 refined a companion measure enacted in the same session, HB495, which had folded a broader Medicaid gender-affirming-care restriction into a bill repealing the state's conversion-therapy protections. The primary sponsor of HB501 was Rep. Marianne Whitaker. Reporting by Louisville Public Media and the Kentucky Lantern described the Medicaid changes as advanced late in the session as part of a wider set of anti-transgender measures pushed by the legislature's Republican majority.

Why we recorded this

Equal protection requires that government not disadvantage people because of who they are. Kentucky HB501 wrote into law that state Medicaid may not pay for cross-sex hormones when they are prescribed to treat gender dysphoria, while leaving coverage of the identical medications intact for every other diagnosis. Conditioning a public health benefit on the patient's gender identity in this way singles out transgender Kentuckians for exclusion. This archive records when government policy withholds equal treatment on the basis of a protected characteristic.

Sources

  1. 25RS HB 501 — legislative record — Kentucky General Assembly primary accessed July 12, 2026
  2. Kentucky HB501 | 2025 | Regular Session — LegiScan secondary accessed July 12, 2026
  3. Kentucky GOP pushed through anti-trans bills and Medicaid changes in eleventh hour — Louisville Public Media investigative accessed July 12, 2026
  4. Ban on Kentucky Medicaid paying for gender-affirming care added to conversion therapy bill — Kentucky Lantern investigative accessed July 12, 2026

See also